ArticlePloS one2020
Metabolomic study of marine Streptomyces sp.: Secondary metabolites and the production of potential anticancer compounds.
Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Secondary metabolite profiling of rare Micromonospora spp. from cold desert of NW Himalayas via multi-omics analysis.Metabolomics : Official journal of the Metabolomic Society · 2026Article
- Biofilm formation in Streptomyces nigra strain KDS4 and characterization of extracellular polymeric substances (EPS) for biomaterial development.World journal of microbiology & biotechnology · 2026Article
- Bioactive pigment production by marine bacteria from Colombian estuarine and deep-sea environments.Scientific reports · 2026Article
- Bacterial Espresso: Evaluating Accelerated Solvent Extraction for Selected Metabolite Recovery fromJournal of natural products · 2026Article
- Integrated holobiont responses of the Antarctic brown seaweedISME communications · 2026Article
- Strategies to decipher silent biosynthetic gene clusters in actinomycetes.Archives of microbiology · 2025Review
- Bioassay-Guided Purification of Cytotoxic Isoflavonoids and Sesquiterpenoids ofIranian journal of biotechnology · 2025Article
- Inhibitory Activity of Compounds Obtained fromPathogens (Basel, Switzerland) · 2025Article
- Direct 3D Mass Spectrometry Imaging Analysis of Environmental Microorganisms.Molecules (Basel, Switzerland) · 2025Article
- Presence of polyketide synthases and nonribosomal peptide synthetase in culturable bacteria associated with Aplysina fulva and Aplysina caissara (Porifera).Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Optimization and characterization of bioactive secondary metabolites from Streptomyces sp CMSTAAHL-4 isolated from mangrove sediment.BMC microbiology · 2025Article
- Gut Microbiota Secondary Metabolites: Key Roles in GI Tract Cancers and Infectious Diseases.Biomedicines · 2025Review
- [Advances in molecular networking technology for discovering emerging contaminants and transformation products].Se pu = Chinese journal of chromatography · 2025Review
- Genomic and Untargeted Metabolomic Analysis of Secondary Metabolites in theJournal of agricultural and food chemistry · 2024Article
- Antibacterial, Antifungal, and Cytotoxic Effects of EndophyticBiomedicines · 2024Article
- Comparative metabolomics study on the secondary metabolites of the red alga,RSC advances · 2024Article
- Metabolic Comparison and Molecular Networking of Antimicrobials inInternational journal of molecular sciences · 2024Article
- Present Status, Limitations, and Prospects of Using Streptomyces Bacteria as a Potential Probiotic Agent in Aquaculture.Probiotics and antimicrobial proteins · 2024Review
- Molecular authentication, metabolite profiling and in silico-in vitro cytotoxicity screening of endophytic3 Biotech · 2024Article
- Rapid Discovery of Substances with Anticancer Potential from Marine Fungi Based on a One Strain-Many Compounds Strategy and UPLC-QTOF-MS.Marine drugs · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Resorting to a One Strain Many Compounds (OSMAC) approach, the marine Streptomyces sp. BRB081 strain was grown in six different media settings over 1, 2, 3 or 7 days. Extractions of mycelium and broth were conducted separately for each media and cultivation period by sonication using methanol/acetone 1:1 and agitation with ethyl acetate, respectively. All methanol/acetone and ethyl acetate crude extracts were analysed by HPLC-MS/MS and data treatment was performed through GNPS platform using MZmine 2 software. In parallel, the genome was sequenced, assembled and mined to search for biosynthetic gene clusters (BGC) of secondary metabolites using the AntiSMASH 5.0 software. Spectral library search tool allowed the annotation of desferrioxamines, fatty acid amides, diketopiperazines, xanthurenic acid and, remarkably, the cyclic octapeptides surugamides. Molecular network analysis allowed the observation of the surugamides cluster, where surugamide A and the protonated molecule corresponding to the B-E isomers, as well as two potentially new analogues, were detected. Data treatment through MZmine 2 software allowed to distinguish that the largest amount of surugamides was obtained by cultivating BRB081 in SCB medium during 7 days and extraction of culture broth. Using the same data treatment, a chemical barcode was created for easy visualization and comparison of the metabolites produced overtime in all media. By genome mining of BRB081 four regions of biosynthetic gene clusters of secondary metabolites were detected supporting the metabolic data. Cytotoxic evaluation of all crude extracts using MTT assay revealed the highest bioactivity was also observed for extracts obtained in the optimal conditions as those for surugamides production, suggesting these to be the main active compounds herein. This method allowed the identification of compounds in the crude extracts and guided the selection of best conditions for production of bioactive compounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.